This product is an aminoglycoside antibiotic. The antibacterial spectrum is similar to that of gentamicin. It has antibacterial effects on Gram-negative bacteria such as Escherichia coli, aerogenes, Klebsiella, Proteus mirabilis, some indole-positive Proteus, Pseudomonas aeruginosa, some Neisseria, some non-pigmented Serratia and Shigella. Among Gram-positive bacteria, Staphylococcus aureus (including β-lactamase-producing strains) is sensitive to this product; Streptococci (including Streptococcus pyogenes, Pneumococcus, Streptococcus faecalis, etc.) are all resistant to this product. Anaerobic bacteria (Bacteroides), Mycobacterium tuberculosis, Rickettsia, viruses and fungi are also resistant to this product. This product is stable to aminoglycoside acetyltransferase AAC (6') produced by bacteria, so it still has antibacterial activity against bacteria that are resistant to kanamycin, gentamicin, amikacin, ribosomycin, etc. due to the production of this enzyme. The minimum inhibitory concentration of this product is 0.1-6.25 mg/L. The mechanism of action of this product is to bind to the bacterial ribosome 30S subunit and inhibit the synthesis of bacterial protein.

This product is an aminoglycoside antibiotic. The antibacterial spectrum is similar to that of gentamicin. It has antibacterial effects on Gram-negative bacteria such as Escherichia coli, aerogenes, Klebsiella, Proteus mirabilis, some indole-positive Proteus, Pseudomonas aeruginosa, some Neisseria, some non-pigmented Serratia and Shigella. Among Gram-positive bacteria, Staphylococcus aureus (including β-lactamase-producing strains) is sensitive to this product; Streptococci (including Streptococcus pyogenes, Pneumococcus, Streptococcus faecalis, etc.) are all resistant to this product. Anaerobic bacteria (Bacteroides), Mycobacterium tuberculosis, Rickettsia, viruses and fungi are also resistant to this product. This product is stable to aminoglycoside acetyltransferase AAC (6') produced by bacteria, so it still has antibacterial activity against bacteria that are resistant to kanamycin, gentamicin, amikacin, ribosomycin, etc. due to the production of this enzyme. The minimum inhibitory concentration of this product is 0.1-6.25 mg/L. The mechanism of action of this product is to bind to the bacterial ribosome 30S subunit and inhibit the synthesis of bacterial protein.

This product is an aminoglycoside antibiotic. The antibacterial spectrum is similar to that of gentamicin. It has antibacterial effects on Gram-negative bacteria such as Escherichia coli, aerogenes, Klebsiella, Proteus mirabilis, some indole-positive Proteus, Pseudomonas aeruginosa, some Neisseria, some non-pigmented Serratia and Shigella. Among Gram-positive bacteria, Staphylococcus aureus (including β-lactamase-producing strains) is sensitive to this product; Streptococci (including Streptococcus pyogenes, Pneumococcus, Streptococcus faecalis, etc.) are resistant to this product. Anaerobic bacteria (Bacteroides), Mycobacterium tuberculosis, Rickettsia, viruses and fungi are also resistant to this product. This product is stable to aminoglycoside acetyltransferase AAC (6') produced by bacteria, so it still has antibacterial activity against bacteria that are resistant to kanamycin, gentamicin, amikacin, ribosomycin, etc. due to the production of this enzyme. The minimum inhibitory concentration of this product is 0.1-6.25 mg/L. The mechanism of action of this product is to bind to the bacterial ribosome 30S subunit and inhibit the synthesis of bacterial protein.

Extract from the above information

This product is a coenzyme that improves the body's metabolism and participates in the metabolism of fat, protein, sugar, nucleic acid and nucleotides in the body. It is also the main source of energy in the body. When energy is needed for absorption, secretion, muscle contraction and biochemical synthesis reactions in the body, adenosine triphosphate is decomposed into adenosine diphosphate and phosphate groups, and energy is released at the same time. Animal experiments have shown that this product can inhibit the slow calcium ion influx of slow-reacting fibers, block or delay the forward conduction in the atrioventricular node reentry pathway, and a large dose may also block or delay the forward and reverse conduction of the bypass; in addition, it also has a short-term and strong effect of enhancing the vagus nerve, thereby terminating arrhythmias caused by atrioventricular node reentry and bypass reentry mechanisms.